https://www.spreaker.com/podcast/biotech-iq--6703806enLife SciencesPodgohttps://d3wo5wojvuv7l.cloudfront.net/t_rss_itunes_square_1400/images.spreaker.com/original/a1330954c03536d8b5ddc4506d0aa05d.jpghttps://www.spreaker.com/podcast/biotech-iq--6703806Fri, 06 Feb 2026 20:45:21 +0000PodgoPodgobooking@podgo.ioIncrease your IQ and understanding of the Biotech industry by listening to interviews with key business leaders who have built successful companies and departments. We discuss everything from the science, clinical operations, clinical development,...falseepisodichttps://www.spreaker.com/episode/a-journey-from-investment-banker-to-the-ceo-of-a-biotech-developing-cancer-therapy-with-bryan-kobel--67270806Bryan Kobel decided to pursue a career in biotech after seeing its massive opportunities to change the world. He sits down with Ammon Rivera to share how he translated his background as an investment banker into his role as the CEO of TC BioPharm, a company that develops cancer therapy. He opens up about finding his purpose in this space that allows him to save lives and molds him into a compassionate leader. Bryan also talks about their allogenic Gamma Delta T Cell therapy platform, which involves injecting isolated Gamma Delta T Cells to treat cancer-stricken patients. He explains how they are continuously evolving this method to make it cost-effective and easily accessible to underserved and economically disadvantaged individuals.
]]>L_wJaf1epWed, 24 Sep 2025 00:00:00 +0000Podgohttps://www.linkedin.com/in/bryan-kobel-330a197/ decided to pursue a career in biotech after seeing its massive opportunities to change the world. He sits down with Ammon Rivera to share how he translated his background as an investment banker into...Bryan Kobel decided to pursue a career in biotech after seeing its massive opportunities to change the world. He sits down with Ammon Rivera to share how he translated his background as an investment banker into his role as the CEO of TC BioPharm, a company that develops cancer therapy. He opens up about finding his purpose in this space that allows him to save lives and molds him into a compassionate leader. Bryan also talks about their allogenic Gamma Delta T Cell therapy platform, which involves injecting isolated Gamma Delta T Cells to treat cancer-stricken patients. He explains how they are continuously evolving this method to make it cost-effective and easily accessible to underserved and economically disadvantaged individuals.
]]>3011false65fullhttps://www.spreaker.com/episode/biotech-chief-people-officer-discusses-how-to-build-company-culture--67270809HMyHUztI7Wed, 17 Sep 2025 00:00:00 +0000PodgoScience will only get you so far in biotech. No matter how ingenious your products are, you will never succeed as a company if you don’t have all the pieces if business development in place. And there is no greater piece than the people piece. As the...2334falsefullhttps://www.spreaker.com/episode/qualigen-therapeutics-how-to-develop-an-oncology-therapeutics-pipeline-from-a-cmo-s-perspective-with-tariq-arshad-md--67270815Qualigen Therapeutics. With their oncology therapeutics pipeline, they could be onto something with their leading asset QN-302.  Join Ammon Rivera as he talks to the Chief Medical Officer of Qualigen Therapeutics, Tariq Arshad, MD, about where they are right now in their therapeutics pipeline. Learn why cancer is the greatest injustice and how Tariq is fighting to stop it. Find out more about their research in Qualigen Therapeutics when it comes to killing these cancer cells. Let's all come together and stop cancer.]]>IYNRlQRmbrWed, 10 Sep 2025 00:00:00 +0000PodgoThere isn’t a cure for cancer yet, but if everyone can come together, we may find that cure sooner rather than later. One biotech company that is trying to solve cancer is https://www.qualigeninc.com/. With their oncology therapeutics pipeline, they...Qualigen Therapeutics. With their oncology therapeutics pipeline, they could be onto something with their leading asset QN-302.  Join Ammon Rivera as he talks to the Chief Medical Officer of Qualigen Therapeutics, Tariq Arshad, MD, about where they are right now in their therapeutics pipeline. Learn why cancer is the greatest injustice and how Tariq is fighting to stop it. Find out more about their research in Qualigen Therapeutics when it comes to killing these cancer cells. Let's all come together and stop cancer.]]>2695false58fullhttps://www.spreaker.com/episode/qualigen-therapeutics-how-do-you-develop-a-successful-therapeutics-pipeline-in-oncology-with-amy-broidrick--67270811Qualigen Therapeutics is a biotechnology company that develops novel therapeutic products to treat adult and pediatric patients with rare cancers. A leading name in the industry, they have decided to build a therapeutics pipeline within the last few years. In this first episode of a three-part series featuring top executives of Qualigen Therapeutics, Ammon interviews Amy Broidrick, the firm’s President and Chief Strategy Officer. She shares what she brings to the table in the company’s transition from a preclinical stage company to a brand new business venture. She also talks about her deep love for market research, her career’s pivotal and most fulfilling moments, and how she deals with negativity.]]>8jZHqNE-fWed, 03 Sep 2025 00:00:00 +0000Podgohttps://www.qualigeninc.com/ is a biotechnology company that develops novel therapeutic products to treat adult and pediatric patients with rare cancers. A leading name in the industry, they have decided to build a therapeutics pipeline within the...Qualigen Therapeutics is a biotechnology company that develops novel therapeutic products to treat adult and pediatric patients with rare cancers. A leading name in the industry, they have decided to build a therapeutics pipeline within the last few years. In this first episode of a three-part series featuring top executives of Qualigen Therapeutics, Ammon interviews Amy Broidrick, the firm’s President and Chief Strategy Officer. She shares what she brings to the table in the company’s transition from a preclinical stage company to a brand new business venture. She also talks about her deep love for market research, her career’s pivotal and most fulfilling moments, and how she deals with negativity.]]>2803false56fullhttps://www.spreaker.com/episode/mapping-the-human-immune-system-using-ai-to-change-drug-development-with-noam-solomon--67270821Nyqj2dr13Wed, 27 Aug 2025 00:00:00 +0000PodgoAI has gone so far as to potentially change drug development, and these developments have the potential to make a difference in people’s lives. On this episode of BioTech IQ, Ammon interviews Noam Solomon, the CEO of Immunai. Immunai is developing an...2900false55fullhttps://www.spreaker.com/episode/going-beyond-the-current-standard-of-care-for-anxiety-depression-and-cns-disorders-with-shawn-singh--67270822Shawn Singh, the CEO and Director of VistaGen Therapeutics, and his team are creating a nasal spray to help people with social anxiety disorder. Just like an inhaler for asthma, this nasal spray can do for social anxiety. Join Ammon Rivera as he talks to Shawn Singh about the PH94B nasal spray. Find out how it works and how far along they are in the process. If they get approved, VistaGen has the opportunity to be the first FDA-approved acute treatment for adults with social anxiety disorder. Discover how VistaGen is going beyond the current standard of care for anxiety, depression, and CNS disorders. ]]>2YefwIdIxWed, 20 Aug 2025 00:00:00 +0000PodgoSocial anxiety disorder is the third most common mental health disorder. Over 23 million Americans alone are affected by it. This disorder can continue to grow into depression and drug abuse, so it's very important to catch it early so it can be...Shawn Singh, the CEO and Director of VistaGen Therapeutics, and his team are creating a nasal spray to help people with social anxiety disorder. Just like an inhaler for asthma, this nasal spray can do for social anxiety. Join Ammon Rivera as he talks to Shawn Singh about the PH94B nasal spray. Find out how it works and how far along they are in the process. If they get approved, VistaGen has the opportunity to be the first FDA-approved acute treatment for adults with social anxiety disorder. Discover how VistaGen is going beyond the current standard of care for anxiety, depression, and CNS disorders. ]]>2777false53fullhttps://www.spreaker.com/episode/harnessing-the-innate-immune-system-by-developing-three-types-of-ipsc-derived-natural-killer-cells-with-daniel-teper--67270818Daniel Teper, Co-Founder and CEO of Cytovia Therapeutics, to talk about the unique technology they’re using to develop a treatment for cancer. Daniel discusses how they’ve developed three types of iPSC-Derived Natural Killer Cells and are now targeting unmet needs in treating hepatocellular carcinoma (HCC). There is a lot of disruptive innovation coming from the biotech industry. Daniel also discusses how the field is dealing with worsening market conditions amidst recent news of a special purpose acquisition with Isleworth Healthcare Corporation. There’s much to learn from this episode, both in medicine and economics.]]>eaIyH4JiiWed, 13 Aug 2025 00:00:00 +0000PodgoCompanies in the biotech space are making contributions to help find a cure for cancer. Today’s guest is no exception. In today’s episode, Ammon Rivera sits down with https://www.linkedin.com/in/danielteper/, Co-Founder and CEO...Daniel Teper, Co-Founder and CEO of Cytovia Therapeutics, to talk about the unique technology they’re using to develop a treatment for cancer. Daniel discusses how they’ve developed three types of iPSC-Derived Natural Killer Cells and are now targeting unmet needs in treating hepatocellular carcinoma (HCC). There is a lot of disruptive innovation coming from the biotech industry. Daniel also discusses how the field is dealing with worsening market conditions amidst recent news of a special purpose acquisition with Isleworth Healthcare Corporation. There’s much to learn from this episode, both in medicine and economics.]]>1931false52fullhttps://www.spreaker.com/episode/cell-cycle-therapy-understanding-the-cell-cycle-biology-to-treat-cancer-with-spiro-rombotis--67270824Cyclacel comes in with all their research into the cell cycle of cancer. Join Ammon Rivera as he talks to Spiro Rombotis about some of Cyclacel's cell cycle therapies. Spiro is the CEO of Cyclacel. His mission is to use cell cycle biology to treat cancer and other serious diseases. Ammon and Spiro go over the use of Cyclin-dependent Kinase and its role in the cell cycle. Spiro also talks about Cyclacel's pipeline and drug candidates. They also go through discussion strategy, the drug approval process, and what it means to fail fast.]]>pIxThktUyWed, 06 Aug 2025 00:00:00 +0000PodgoCell cycle biology is key to understanding cancer. You have to hit the cancer cells early before they become smart and adapt. There is a stage in the cell cycle called mitosis. This is where, if done right, can cause cancer cells to suicide. This is...Cyclacel comes in with all their research into the cell cycle of cancer. Join Ammon Rivera as he talks to Spiro Rombotis about some of Cyclacel's cell cycle therapies. Spiro is the CEO of Cyclacel. His mission is to use cell cycle biology to treat cancer and other serious diseases. Ammon and Spiro go over the use of Cyclin-dependent Kinase and its role in the cell cycle. Spiro also talks about Cyclacel's pipeline and drug candidates. They also go through discussion strategy, the drug approval process, and what it means to fail fast.]]>3329false51fullhttps://www.spreaker.com/episode/can-lineage-cell-therapeutics-proprietary-cell-based-therapy-platform-change-treatment-development--67270829Brian Culley is one of the leaders in this field. He is the CEO of Lineage Cell Therapeutics, a company developing treatments for multiple indications based on their proprietary cell-based therapy platform. Leveraging in-house manufacturing, they are attacking multiple indications from ophthalmology to immuno-oncology. In this episode, Brian joins Ammon Rivera to explain what their strategy is, where they are currently in the development process, and where they’re going from there.]]>sD5dZi7RoWed, 30 Jul 2025 00:00:00 +0000PodgoHave you ever thought about having replacement parts for your body? It sounds like science fiction, but it’s now as real as the eyes you’re using to read this, thanks to cell-based therapy. https://www.linkedin.com/in/brian-culley-7b219a1/ is one of...Brian Culley is one of the leaders in this field. He is the CEO of Lineage Cell Therapeutics, a company developing treatments for multiple indications based on their proprietary cell-based therapy platform. Leveraging in-house manufacturing, they are attacking multiple indications from ophthalmology to immuno-oncology. In this episode, Brian joins Ammon Rivera to explain what their strategy is, where they are currently in the development process, and where they’re going from there.]]>2332false50fullhttps://www.spreaker.com/episode/global-tensions-and-supply-chains-and-their-effect-on-biotech-guillermo-morales-phd-ceo-of-innoventyx--67270825Guillermo Morales, PhD, CEO of Innoventyx. Guillermo makes us privy to the issues brought on by COVID-19 and the geopolitical tensions such as the Russia-Ukraine conflict. He also discusses intellectual property in greater depth and why it’s important to act fast when patenting your product. Moving from Latin America to the United States, Guillermo also shares his experience learning and re-learning the science in both languages and how it impacts communication. Don’t miss out on their enlightening conversation by tuning in!]]>AQhDDpkTFWed, 23 Jul 2025 00:00:00 +0000PodgoThe biotech industry has been bombarded with disruptions in recent years, from a global pandemic to rising global tensions. How are they dealing with the supply chain issues and how else has it impacted the industry? In this episode, Ammon Rivera sits...Guillermo Morales, PhD, CEO of Innoventyx. Guillermo makes us privy to the issues brought on by COVID-19 and the geopolitical tensions such as the Russia-Ukraine conflict. He also discusses intellectual property in greater depth and why it’s important to act fast when patenting your product. Moving from Latin America to the United States, Guillermo also shares his experience learning and re-learning the science in both languages and how it impacts communication. Don’t miss out on their enlightening conversation by tuning in!]]>3214false49fullhttps://www.spreaker.com/episode/can-hepion-pharmaceuticals-develop-the-first-treatment-approved-for-nash-with-robert-foster-pharm-d-phd--67270831Robert Foster Pharm D, PhD, CEO of Hepion Pharmaceuticals. Robert brings 30 years of experience to this discussion and shares with us details of his background that led him to where he is today. We also discuss Hepion Pharmacetuicals current clinical trials to development treatments targeting chronic liver diseases including NASH, cancer, and chronic hepatitis virus infection. A quarter of the people in the US have fatty livers and of those, about a fifth will likely develop NASH. It’s a big problem that affects a lot of people. The company’s lead drug candidate, Rencofilstat, reduces liver fibrosis and hepatocellular carcinoma tumor burden in experimental models of NASH. Tune in to learn more about their pharmaceutical development process and other possibilities with the drug in terms of treatment.]]>NlrPs58MWjWed, 16 Jul 2025 00:00:00 +0000PodgoOn this episode of BioTech IQ, Ammon Rivera interviews https://hepionpharma.com/about/leadership/robert-foster/, CEO of https://hepionpharma.com/. Robert brings 30 years of experience to this discussion and shares with us details of his background...Robert Foster Pharm D, PhD, CEO of Hepion Pharmaceuticals. Robert brings 30 years of experience to this discussion and shares with us details of his background that led him to where he is today. We also discuss Hepion Pharmacetuicals current clinical trials to development treatments targeting chronic liver diseases including NASH, cancer, and chronic hepatitis virus infection. A quarter of the people in the US have fatty livers and of those, about a fifth will likely develop NASH. It’s a big problem that affects a lot of people. The company’s lead drug candidate, Rencofilstat, reduces liver fibrosis and hepatocellular carcinoma tumor burden in experimental models of NASH. Tune in to learn more about their pharmaceutical development process and other possibilities with the drug in terms of treatment.]]>3157false47fullhttps://www.spreaker.com/episode/how-is-translational-genomics-reducing-background-noise-in-multi-disease-detection-with-aiguo-adam-zhang--67270812DiaCarta, a diagnostics company using translational genomics and molecular precision technology to develop ways of detecting disease. In this episode of BioTech IQ, Ammon Rivera interviews its CEO, Adam Zhang. Their patented technology reduces the "background noise" in testing, allowing for the detection of the "bad actor." Join in to learn the processes behind their work, what this means to the future of testing and treating diseases, and where the company is headed. Don't miss out!]]>NdQ6gr4mOWed, 09 Jul 2025 00:00:00 +0000PodgoSome of the main problems with sequencing in identifying mutations are its cost and the time it takes. Fortunately, with the rapid growth of technology, revolutionary products that simplify processes are being made. One of those is...DiaCarta, a diagnostics company using translational genomics and molecular precision technology to develop ways of detecting disease. In this episode of BioTech IQ, Ammon Rivera interviews its CEO, Adam Zhang. Their patented technology reduces the "background noise" in testing, allowing for the detection of the "bad actor." Join in to learn the processes behind their work, what this means to the future of testing and treating diseases, and where the company is headed. Don't miss out!]]>2434false46fullhttps://www.spreaker.com/episode/addressing-one-of-the-world-s-biggest-drivers-of-disease-inflammation-with-jim-woody-m-d-ph-d-ceo-180-life-sciences--67270847180 Life Sciences, Jim Woody about anti-TNFs and the trial process behind them. Jim’s goal is to address one of the biggest drivers of disease – inflammation. Learn more about Jim’s career as a venture capitalist. Find out why trials need to be uniform and randomized. And, discover what it takes to run a biotech company today.]]>YcabnyLRSWed, 02 Jul 2025 00:00:00 +0000PodgoTNF is a protein that contributes to inflammation. Anti-TNFs can be used to stabilize this and stop the inflammation. It’s used for diseases like arthritis and psoriasis. Discover how clinical trials are done so these medicines and anti-TNFs can be...180 Life Sciences, Jim Woody about anti-TNFs and the trial process behind them. Jim’s goal is to address one of the biggest drivers of disease – inflammation. Learn more about Jim’s career as a venture capitalist. Find out why trials need to be uniform and randomized. And, discover what it takes to run a biotech company today.]]>2779false44fullhttps://www.spreaker.com/episode/35-can-biomea-change-the-world-with-irreversible-drugs-and-covalent-bonds-thomas-butler-ceo-biomea-fusion--67270853
https://biomeafusion.com/
https://thebiotechiqpodcast.com/podcast/]]>1mqFE5cCTWed, 25 Jun 2025 00:00:00 +0000PodgoTom shares with us some of his journey and how that led him to co-found Biomea Fusion. We discuss some of the science behind irreversible drugs and covalent bonding. Using their fusion system there is greater potential for high selectivity, deep...
https://biomeafusion.com/
https://thebiotechiqpodcast.com/podcast/]]>3884falsefullhttps://www.spreaker.com/episode/33-reducing-friction-at-clinical-trial-start-up-sam-searcy-ceo-of-clinistart--67270842
https://clinistart.com/]]>Z6km18zRVWed, 18 Jun 2025 00:00:00 +0000PodgoCliniStart launched to provide innovative tech-enabled solutions focused on global investigator contracts, budgets, and payments. And they did all of this just as the COVID-19 pandemic was hitting. This gave them an opportunity to shift and adapt. In...
https://clinistart.com/]]>3231falsefullhttps://www.spreaker.com/episode/32-people-the-most-valuable-asset-a-business-has-brenda-sousa-chief-hr-officer--67270827
#BiotechIQ #Biotech #Drugdevelopment #Recruiting #Staffing]]>CDbVhx5w_Wed, 11 Jun 2025 00:00:00 +0000PodgoOn this episode we have Brenda Sousa, previously the Chief Human Resources Officer with Constellation Pharmaceuticals. Brenda shares with us part of her backstory and entry into the world of Biotech. We discuss people, culture, the function of HR, and...
#BiotechIQ #Biotech #Drugdevelopment #Recruiting #Staffing]]>3865falsefullhttps://www.spreaker.com/episode/31-managing-cro-relationships-and-unique-business-models-stewart-hallet-coo-sfj-pharmaceuticals--67270823


#BioTechIQ #ClinicalOperations #DrugDevelopment #Podcasts]]>I3E1ks_oEWed, 04 Jun 2025 00:00:00 +0000PodgoIn this episode of BioTech IQ Ammon interviews Stewart Hallet the COO of SFJ Pharmaceuticals, a specialty pharmaceutical company with a unique business model. The discussion touches on a number of things in clinical operations including working with...


#BioTechIQ #ClinicalOperations #DrugDevelopment #Podcasts]]>3860falsefullhttps://www.spreaker.com/episode/30-brazen-bio-part-ii-live-and-in-person--67270826Hh7QvEkLMWed, 28 May 2025 00:00:00 +0000PodgoCo-founders Shawn Carbonell and Brent Witgen discuss the progress of the 1st cohort (BRZN1) as they are well into the Brazen Bio program. We also get the chance to interview one of the founders currently in the program. We discuss what he is working...2414falsefullhttps://www.spreaker.com/episode/29-why-do-we-resist-applying-clinical-psychology-to-clinical-trials-kathleen-starr-phd-evp-behavioral-insights-syneos-health--67270841
https://www.amazon.com/Why-Resist-Surprising-Healthcare-Communicators/dp/057854766X]]>CODNUirKlWed, 21 May 2025 00:00:00 +0000PodgoKathleen shares fantastic insights on understanding behavioral psychology and how it applies to successful clinical trials. We had a great conversation that touched on increasing diversity in trials to understanding our own behavior and how we can...
https://www.amazon.com/Why-Resist-Surprising-Healthcare-Communicators/dp/057854766X]]>3469falsefullhttps://www.spreaker.com/episode/28-vaccine-durability-diversified-pipeline-winning-strategy-seth-lederman-md-ceo-tonix-pharmaceuticals--67270834yy_kvhFTXWed, 14 May 2025 00:00:00 +0000PodgoSeth Lederman is the CEO of Tonix Pharmaceuticals and a physician scientist with a two decades of research experience. Prior to becoming an entrepreneur, he was an Associate Professor at Columbia University. Dr. Lederman’s groundbreaking research led...3380falsefullhttps://www.spreaker.com/episode/27-how-do-you-effectively-manage-the-cmc-process-with-doug-looker-phd--67270846
During the recording and editing of this episode Doug was the VP of Preclinical Development and Manufacturing at Amicrobe, Inc. Therefore the intro does not reflect his currrent position.

https://validustherapeutics.com/


]]>w025PUudEWed, 07 May 2025 00:00:00 +0000PodgoDoug Looker is the VP of Operations with Validus Cellular Therapeutics. Validus is using cellular therapy to target infections by fighting the biology of antimicrobial resistance by activating the biology of the mammalian immune system. Doug walks us...
During the recording and editing of this episode Doug was the VP of Preclinical Development and Manufacturing at Amicrobe, Inc. Therefore the intro does not reflect his currrent position.

https://validustherapeutics.com/


]]>1762falsefullhttps://www.spreaker.com/episode/26-how-do-you-know-the-right-path-of-development-mike-rea-ceo-idea-pharma--67270835IDEA Pharma and author of the Pharmaceutical Innovation Index. He just launched a new company, Protodigm, that’s mission is to act as a pharma/biotech skunkworks that can test and troubleshoot drug development and avoid failure by determining the best possible development paths. Here’s the release. He is an expert on all things drug development and has positioned 8 of the 15 biggest drug launches of the last 5 years. Mike is a contributor to Fortune, STAT, and Endpoints and also hosts his own podcast. https://podcast.ideapharma.com/Mike also refers to Protodigm as a next generation CRO.]]>y2Dzo5ebfWed, 30 Apr 2025 00:00:00 +0000PodgoMike is the CEO of https://www.ideapharma.com/ and author of the https://www.ideapharma.com/pii/. He just launched a new company, https://www.protodigm.co/, that’s mission is to act as a pharma/biotech skunkworks that can test and troubleshoot drug...IDEA Pharma and author of the Pharmaceutical Innovation Index. He just launched a new company, Protodigm, that’s mission is to act as a pharma/biotech skunkworks that can test and troubleshoot drug development and avoid failure by determining the best possible development paths. Here’s the release. He is an expert on all things drug development and has positioned 8 of the 15 biggest drug launches of the last 5 years. Mike is a contributor to Fortune, STAT, and Endpoints and also hosts his own podcast. https://podcast.ideapharma.com/Mike also refers to Protodigm as a next generation CRO.]]>3281falsefullhttps://www.spreaker.com/episode/25-potential-tumor-immunity-grant-yonehiro-cbo-bolt-biotherapeutics--67270817
Bolt Bio focuses on the development of ISACs – immune-stimulating antibody conjugates – which are anti-cancer drugs comprised of two main parts: a tumor targeting antibody attached to an immune system stimulant. This stimulant activates both the innate and adaptive arms of the immune system, potentially turning a “cold” tumor environment into a “hot” one. Their lead therapeutic candidate, BDC-1001, targets HER2+ tumors and is currently in Phase 1/2 trials.

https://www.boltbio.com/
 
https://www.globenewswire.com/news-release/2021/06/02/2240329/0/en/Genmab-and-Bolt-Biotherapeutics-Announce-Oncology-Research-and-Development-Collaboration.html]]>TR9wbku7_9Wed, 23 Apr 2025 00:00:00 +0000PodgoGrant is the Chief Business Officer with Bolt BioTherapeutics. Bolt Bio recently went public in February this year and announced a partnership with Genmab. Grant talks business development strategy and helping to navigate Bolt through their recent...
Bolt Bio focuses on the development of ISACs – immune-stimulating antibody conjugates – which are anti-cancer drugs comprised of two main parts: a tumor targeting antibody attached to an immune system stimulant. This stimulant activates both the innate and adaptive arms of the immune system, potentially turning a “cold” tumor environment into a “hot” one. Their lead therapeutic candidate, BDC-1001, targets HER2+ tumors and is currently in Phase 1/2 trials.

https://www.boltbio.com/
 
https://www.globenewswire.com/news-release/2021/06/02/2240329/0/en/Genmab-and-Bolt-Biotherapeutics-Announce-Oncology-Research-and-Development-Collaboration.html]]>3142falsefullhttps://www.spreaker.com/episode/24-a-fellowship-program-for-biotech-founders-meet-brazen-bio--67270840
Shawn Carbonell, MD, PhD quit his neurosurgery residency to found his first biotech startup a decade ago. He had invented and developed a first-in-class cancer drug which is currently in phase 1 clinical trial.Brent Witgen, PhD had been in big pharma for the past decade, with direct involvement in over a dozen drug and device regulatory filings across multiple areas of human disease. He has built high-performing biotech teams in the US, EU, and Asia.Together they have recently launched Brazen Bio to help biotech founders advance human health. Brazen Bio is building a turnkey incubator program with state-of-the-art laboratory access, including specialized equipment, technical support, expert advisors and accommodation. Based in LA they are planning to run the first cohort of founders through the program this year.  https://wefunder.com/brazenbio/https://www.linkedin.com/company/brazenbio/https://www.brazen.bio]]>zFlrLVatiWed, 16 Apr 2025 00:00:00 +0000PodgoThe founders of Brazen Bio discuss how their program is helping potential biotech founders prove their concepts and launch their company. Be Brazen! Shawn Carbonell, MD, PhD quit his neurosurgery residency to found his first biotech startup a decade...
Shawn Carbonell, MD, PhD quit his neurosurgery residency to found his first biotech startup a decade ago. He had invented and developed a first-in-class cancer drug which is currently in phase 1 clinical trial.Brent Witgen, PhD had been in big pharma for the past decade, with direct involvement in over a dozen drug and device regulatory filings across multiple areas of human disease. He has built high-performing biotech teams in the US, EU, and Asia.Together they have recently launched Brazen Bio to help biotech founders advance human health. Brazen Bio is building a turnkey incubator program with state-of-the-art laboratory access, including specialized equipment, technical support, expert advisors and accommodation. Based in LA they are planning to run the first cohort of founders through the program this year.  https://wefunder.com/brazenbio/https://www.linkedin.com/company/brazenbio/https://www.brazen.bio]]>2289falsefullhttps://www.spreaker.com/episode/23-targeting-treatment-related-toxicities-michael-mccullar-ceo-onquality-pharmaceuticals--67270854
https://twitter.com/onquality_rx
https://www.linkedin.com/company/onquality-pharmaceuticals-ltd/
https://www.onqualityrx.com/]]>QAqKNJguAWed, 09 Apr 2025 00:00:00 +0000PodgoMike discusses the advancements that OnQuality Pharmaceuticals is making toward to the treatment of toxicities caused by cancer treatments. Mike also shares with us the challenges and importance of strong leadership in our evolving workforce. ...
https://twitter.com/onquality_rx
https://www.linkedin.com/company/onquality-pharmaceuticals-ltd/
https://www.onqualityrx.com/]]>2846falsefullhttps://www.spreaker.com/episode/22-regulatory-affairs-strategy-w-dr-jethro-ekuta-vp-global-ra--67270833sstZfCc-LWed, 02 Apr 2025 00:00:00 +0000PodgoDr. Ekuta helps to educate us on the function of regulatory affairs by sharing an acronym he calls RCI. Regulatory Requirements, Compliance, and Interaction. He shares how regulatory affairs professionals can had value to companies at all stages of...3569falsefullhttps://www.spreaker.com/episode/21-research-and-development-tax-credits--67270836UFibUaaZDWed, 26 Mar 2025 00:00:00 +0000PodgoLet's talk a little bit of tax and financial strategy! On this episode we have guests Derick Van Ness, a tax/financial strategist and owner of Big Life Financial and Justin Maxwell, President of Small Business Incentive Consultants. They discuss in...2166falsefullhttps://www.spreaker.com/episode/20-can-longevity-really-be-extended-eric-leire-md-ceo-genflow-biosciences--67270857F-l_Eyd0JWed, 19 Mar 2025 00:00:00 +0000PodgoDr. Leire discusses some of his background and the amazing things that GenFlow Biosciences are doing to develop gene therapies that slow or reverse aging in humans an dogs.2986falsefullhttps://www.spreaker.com/episode/19-bing-du-md-senior-director-global-patient-safety-beigene-ltd--67270839GQUdsZ9AldWed, 12 Mar 2025 00:00:00 +0000PodgoDr. Du shares how he was chosen to study medicine in China and how he immigrated to the United States for a research fellowship. He subsequently went into industry and drug safety. We discuss some of the details and nuances of the medical case review...2898falsefullhttps://www.spreaker.com/episode/18-ed-tucker-md-mba-chief-medical-officer-mirum-pharmaceuticals--67270860UTyB0pcOfiWed, 05 Mar 2025 00:00:00 +0000PodgoDr. Tucker shares insight from his career on leadership to team building. He also discusses some of the the great things Mirum is doing to fight rare liver diseases in children. 2636falsefullhttps://www.spreaker.com/episode/17-patti-engel-ceo-of-engage-health-discusses-rare-disease--67270852oZs3QUKM9Wed, 26 Feb 2025 00:00:00 +0000PodgoPatti started in the Rare Disease space back when it wasn't as well known. Her career led her to founding Engage Health a company that is helping to solve some of the unique challenges faced with patient recruitment in Rare Disease.2856false17fullhttps://www.spreaker.com/episode/16-amy-baxter-md-faap-facep-founder-and-ceo-of-pain-care-labs--67270843
https://shop.paincarelabs.com/]]>VPg0KGkS-Wed, 19 Feb 2025 00:00:00 +0000PodgoDr. Baxter practiced pediatric emergency medicine which led her to discover a common challenge people face; fear of needles and needle pain. She went on to develop a medical device called Buzzy. This has now evolved into another device called...
https://shop.paincarelabs.com/]]>2989falsefullhttps://www.spreaker.com/episode/15-david-chonzi-md-global-head-of-pve-with-instil-bio--67270856S8M2w80OWWed, 12 Feb 2025 00:00:00 +0000PodgoDr. Chonzi started his career in pharma/biotech as a drug safety physician learning both pre and post-market PV.  Since then he has gained a large amount of experience helping companies develop their PV/drug safety function in the pre NDA and the NDA...2692falsefullhttps://www.spreaker.com/episode/14-juliana-oliveira-md-phd-vp-clinical-development-viking-therapeutics--67270845ySEbxJDbZnWed, 05 Feb 2025 00:00:00 +0000PodgoDr. Oliveira discusses some of her background and uses her wealth of knowledge in drug development to discuss the development of a phase III clinical trial. 2829falsefullhttps://www.spreaker.com/episode/13-jo-bhakdi-founder-and-ceo-of-quantgene--67270837R6uC7w45UWed, 29 Jan 2025 00:00:00 +0000PodgoQuantgene has combined precision genomics, machine learning, and a new perspective to detect cancers at early stages. By doing this they have brought one of the biggest needle movers to the market for beating cancer, catching it at an early enough...2058falsefullhttps://www.spreaker.com/episode/12-james-kirwin-coo-sfa-therapeutics-and-experienced-clinical-operations-expert--67270851bO2RhQNVDWed, 22 Jan 2025 00:00:00 +0000PodgoJames Kirwin has worked for some of the most well-known and successful large pharma organizations and successful start-up biotech firms. He has been on the front lines and cutting-edge of clinical operations strategy and has been directly part of...2815falsefullhttps://www.spreaker.com/episode/11-michelle-mcguinness-pharmaceutical-compliance-partners--67270859VPyqwWDJzQWed, 15 Jan 2025 00:00:00 +0000PodgoMichelle has as a long and successful history leading compliance, quality assurance, and regulatory affairs. She discusses the difference between QA and Regulatory Affairs and how they affect both clinical trials and commercialization. Michelle also...3159falsefullhttps://www.spreaker.com/episode/10-aleisha-dobbins-phd-mba-qa-and-gcp-consultant--672708639e_uZQ8iCfWed, 08 Jan 2025 00:00:00 +0000PodgoAleisha shares how she became an expert consultant in helping clients with GCP Auditing, building functioning QA operations, and getting them inspection ready. All critical functions to not only manufacturing but running successful clinical trials as...2434falsefullhttps://www.spreaker.com/episode/9-salah-kivlighn-phd-the-kivlighn-group--67270866®, a required vaccine for children in the US, resulting in an $800M franchise (Merck & Co.)Very interesting insights shared!]]>CH5rS8rngBWed, 01 Jan 2025 00:00:00 +0000PodgoDr. Kivilghn is a senior Pharmaceutical and biotech executive with a rare blend of science and business acumen. Dr. Kivlighn discusses what drove him into the industry, controversial challenge trials, and how having a science background contributed to...®, a required vaccine for children in the US, resulting in an $800M franchise (Merck & Co.)Very interesting insights shared!]]>2951falsefullhttps://www.spreaker.com/episode/8-rolf-linke-md-chief-medical-officer-sfj-pharmaceuticals--67270838dSSQ-XmrtWed, 25 Dec 2024 00:00:00 +0000PodgoDr. Linke shares his wealth of global drug development knowledge by discussing clinical trials and interacting with US, European, Chinese, and other regulatory agencies! Dr. Linke also shares his career progression and what drove some of the decisions...3104falsefullhttps://www.spreaker.com/episode/7-gwen-nichols-md-chief-medical-officer-the-leukemia-lymphoma-society--67270858jiukEunGtWed, 18 Dec 2024 00:00:00 +0000PodgoA trained Oncologist and physician scientist Dr. Nichols discusses what she has seen from working as an academic in research on the front lines as a principal investigator to transitioning into pharma and now in the non-profit setting.3066false7fullhttps://www.spreaker.com/episode/6-doniel-jackson-md-head-of-drug-safety-and-pharmacovigilance-mei-pharma--67270861CkKpTQyvF4Wed, 11 Dec 2024 00:00:00 +0000PodgoDoniel Jackson, MD is a 24+ year Drug Safety and PV veteran in the pharmaceutical industry. Dr. Jackson and I discuss aspects of Drug Safety and Pharmacovigilance and how it is a critical part to successful submission, registration, and post-marketing. 3265falsefullhttps://www.spreaker.com/episode/5-gurdyal-kalsi-md-chief-medical-officer-asklepion-pharmaceuticals--672708507tGdD8YcCWed, 04 Dec 2024 00:00:00 +0000PodgoDr. Kalsi shares some insight on the difference between vaccine clinical trials vs. rare disease vs. oncology. While practicing medicine, experiences working as a principal investigator drove Dr. Kalsi to pursue a medical degree in pharmaceutical...2223falsefullhttps://www.spreaker.com/episode/4-ross-o-youngs-founder-and-ceo-of-biosortia-pharmaceuticals--67270855_avICGSsbWed, 27 Nov 2024 00:00:00 +0000PodgoThrough an interesting turn of events Biosortia discovered they had access to large amounts of Aquatic Microbiome. With a broad range of capabilities they are able to extrapolate this into drug discovery. Ross believes that Biosortias ability to mine...2788falsefullhttps://www.spreaker.com/episode/3-dana-dornsife-ceo-lazarex-cancer-foundation--67270865B6fQ5OKRQWed, 20 Nov 2024 00:00:00 +0000PodgoWhen Dana's brother-in-law was diagnosed with pancreatic cancer she helped her family discover the power of access to clinical trials. That led her founding Lazarex Cancer Foundation, a non-profit organization that helps people find clinical trials...3138false13fullhttps://www.spreaker.com/episode/2-guillermo-morales-ceo-innoventyx--672708620HugpsWaBlWed, 13 Nov 2024 00:00:00 +0000PodgoDr. Morales discusses how COVID-19 affects the clinical trial supply chain, IP Strategy, and transitioning from pre-clinical to clinical.2330falsefullhttps://www.spreaker.com/episode/1-steven-norton-chief-drug-development-officer-elevar-therapeutics--67270864baF0WsOfBWed, 06 Nov 2024 00:00:00 +0000PodgoSteve discusses adapting to COVID-19, hiring, and the challenges of drug development2091falsefullhttps://www.spreaker.com/episode/coming-soon-biotech-iq--67270849VIv4fpFEloWed, 30 Oct 2024 00:00:00 +0000PodgoOn August 14, 2020, Identifyd Life Sciences launches, Biotech IQ hosted by Ammon Rivera. A podcast that interviews those at the cutting edge and front lines of drug development. Ammon interviews people from all aspects of biotech and pharma!106falsefull